Miksei ole?
Source:
BusinessPDFApril 30, 2021. Worldwide Safety. “5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF
PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021.” FDA-CBER-2021-5683-0000054. Pfizer Inc.
https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdfSama
PF-07302048 löytyy kyllä kansilehdeltä:
https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdfResponsible Party: BioNTech SE
ClinicalTrials.gov Identifier:
NCT04368728 History of Changes
Other Study ID Numbers: C4591001
2020-002641-42 ( EudraCT Number )
First Posted: April 30, 2020 Key Record Dates
Last Update Posted: October 27, 2021
Last Verified: October 2021
Study Sponsor: BioNTech
Study Conducted By: Pfizer
Study Intervention Number:
PF-07302048Study Intervention Name: RNA-Based COVID-19 Vaccines
US IND Number: 19736
EudraCT Number:
2020-002641-42Protocol Number: C4591001
Phase: 1/2/3
Short Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and
Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals